Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

Health-care companies ticked up, but lost ground during a generally positive week for the stock market amid fears about the implications of a tight presidential race for health-care regulation.

This was the stock's second consecutive day of gains.

Regeneron buys ex-Quad Graphics facility in Saratoga Springs ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

Ever since the Supreme Court's decision in Dickinson v. Zurko, federal courts (including the Federal Circuit) are compelled under the ...

SARATOGA, N.Y. (WNYT)- Regeneron says they have purchased the sprawling former Quad Graphics site on Duplainville Road in ...

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotypeFollowing recent approvals in the EU and China, the US approval is ...

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and makes ...

Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi ...